parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.04 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in late primary spermatocytes	0.75
chemistry Open Targets	reachable by antibody	0.36
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 6008

receipt 6017: ACSL6 in dopamine neurons, braak

power: full sample -0.12 (p 0.646, n 18), 95% CI -0.55 to +0.37. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.12 (p 0.646, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.37 (p 0.127, n 18). could be the mix.
skeptic: leave-one-out range -0.26 to -0.01, sign flips 0; without severely affected donors -0.12 (p 0.646, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ACSL6 in dopamine neurons.

case closed: nothing better to follow up.

receipt 6016: ACSL6 in astrocytes, braak

power: full sample +0.15 (p 0.555, n 18), 95% CI -0.34 to +0.58. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.15 (p 0.555, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.14 (p 0.579, n 18). could be the mix.
skeptic: leave-one-out range +0.03 to +0.26, sign flips 0; without severely affected donors +0.15 (p 0.555, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ACSL6 in astrocytes.

case closed: nothing better to follow up.

loading the receipts